Patent details
LUC00314 Product Name: Belantamab mafodotin
Basic Information
- Publication number:
- LUC00314
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP181639428
- Legal Status:
- Pending & Published
- Application number:
- LUC00314
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/20/1474
- Marketing Authorization Type:
- Marketing Authorization Date:
- 26/08/2020
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 07/09/2023
- First Marketing Authorization date:
- 26/08/2020
- Grant date:
- Activation date:
- Publication date:
- 07/09/2023
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 26/08/2035
- SPC Extension Expiration:
- 26/08/2035
- Rejection date:
- Withdrawal date:
Owner
- From:
- 07/09/2023
- Name:
- Glaxo Group Limited
- Address:
- GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom (GB)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 07/09/2023
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2023/11
- Publication date:
- 05/10/2023
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 31/05/2032
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 07/09/2023 | Application Form | 3 |
| 07/09/2023 | Marketing authorization | 3 |
| 07/09/2023 | Summary of the product caracteristics | 40 |
| 07/09/2023 | MA publication | 8 |
| 07/09/2023 | Outgoing Correspondence | 1 |
| 07/09/2023 | Publication | 1 |